FINWIRES · TerminalLIVE
FINWIRES

加拿大帝国商业银行(CIBC)预计,加拿大消费者支出短期内将放缓甚至停滞,利率将维持不变。

By

-- “消费者的消费动向通常决定了利率的走向,”加拿大帝国商业银行(CIBC)安德鲁·格兰瑟姆在本周的“展望未来一周”专栏中写道。 格兰瑟姆表示,在当前环境下尤其如此,因为强劲的消费支出将使更多公司能够把成本上涨转嫁给消费者,从而可能引发通胀压力扩大,进而促使加拿大央行采取行动。他还补充道,根据近期零售销售数据,第一季度消费者商品支出创下自2024年底以来的最佳季度表现,人均支出也达到2021年以来的最高水平。 然而,加拿大帝国商业银行(CIBC)认为,短期内消费者支出更有可能放缓甚至停滞,这将降低通胀压力传导的可能性,并使利率在2026年之前保持稳定。 格兰瑟姆表示:“首先,近期的消费激增似乎建立在不稳固的基础之上,这增加了支出再次降温或过去的强劲势头仅仅是统计误差的可能性。即使在近期汽油价格飙升推高通胀之前,由于疲软的劳动力市场对名义收入的影响,实际可支配收入在2025年最后一个季度就已经下降。今年迄今为止的证据表明,就业增长乏力,失业率总体呈横盘整理趋势,这令人对总体收入回升缺乏信心。能源价格可能需要在较长时间内保持高位,才能提振该行业的招聘和工资水平。” “但我们已经必须考虑近期汽油价格飙升的负面影响,自3月初以来,平均而言,此次飙升已使家庭损失约0.7%的收入。”年度总收入。虽然联邦燃油消费税的暂时中止有所帮助,但除非西德克萨斯轻质原油(WTI)价格回落至每桶75美元左右(距离目前的水平还有很长的路要走),否则它无法完全抵消全球油价上涨带来的压力。 “联邦政府即将出台另一项援助措施,提高对低收入和中等收入家庭的福利(并将其更名为加拿大食品和必需品福利),同时还将在6月初发放一次性补贴。对于领取这项补贴的家庭来说,这笔钱或许能够抵消油价上涨迄今为止对他们钱包造成的损失。然而,这笔补贴总额仅占可支配收入的约0.3%,不足以抵消目前汽油价格上涨对消费能力造成的负面影响。 “因此,总体而言,家庭支出更有可能再次放缓,而不是继续近期的增长势头。要想看到更乐观的前景,我们需要联邦政府或省政府更快地降低汽油价格和/或采取进一步的支持措施。今天公布的3月份零售销售预估值可能已经预示着经济增速放缓。虽然0.6%的名义增长率看起来不错,但实际销量增长可能微乎其微,甚至略有下降。 “加拿大央行下周不会急于就汽油价格上涨是否会引发更广泛的通胀压力做出明确判断。届时发布的货币政策报告很可能延续3月份会议的基调,预测近期总体通胀率将出现飙升,但核心通胀率的上升幅度要小得多,也更为缓慢。消费者支出预测的任何改善都可能仅仅反映了第一季度意外的强劲增长,而非对未来前景更为乐观的看法。如果未来支出趋势趋于平缓,那么到2026年利率可能无需调整。”

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD